SMSarah Masyuko

Sarah Masyuko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah Masyuko has a total of 201 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Scope of Practice Laws Affecting Team‐Based Heart Disease Care in Rural America: Policy Challenges and Opportunities

    by Jeff Lane, Signe Burchim, Amanda Li, Janessa M. Graves, Chris Longenecker, Sarah Masyuko, Jennifer Bacci, Sarah Gimbel, Allison Webel, Margaret Hammersla, et al.

    Background: Heart disease is the leading cause of death in the United States with a disproportionate impact in rural America, and health worker shortages contribute to these disparities. Team‐based heart disease care models can help mitigate health worker shortages, but lack of role clarity and restrictive scope of practice laws can be a barrier to their implementation. Methods: To better understand the intersection of licensed scope of practice laws with rural heart disease care, we performed a legal epidemiology analysis to identify and describe licensed scope of practice laws for 9 health worker cadres in 13 state and federal jurisdictions for 8 heart disease services. Results: We found substantial ambiguity, variation, and some important gaps, which may undermine the predictability of regulatory and reimbursement environments and hinder implementation of innovative team‐based care models. Conclusions: Three policy opportunities to address the identified gaps include: (1) linking licensed scope of practice definitions to the scope of accredited training curricula, (2) shifting away from collaborative practice agreements to define licensed scope of practice, and (3) prohibiting insurance plans from conditioning reimbursement based solely on provider cadre.

  • Open Access

    Improving HIV assisted partner services outcomes by eliciting additional partners after the initial encounter

    by George Otieno, Sarah Masyuko, Unmesha Roy Paladhi, Edward Kariithi, Monisha Sharma, Hanley Kingston, Harison Lagat, David A. Katz, Beatrice Wamuti, Paul Macharia, et al.

    Most assisted partner services (APS) programs elicit partners at the time of HIV diagnosis when index clients may be reluctant to name all partners. Little is known about the benefits of ongoing partner elicitation after the initial visit. We utilized data collected in an APS implementation study across 31 facilities in western Kenya from August 2019 to June 2022. HIV testing service providers offered APS to consenting female index clients and asked them to name their male partners both at initial diagnosis and during follow-up clinic visits for 12 months. Partners were traced and offered HIV testing. Using multivariable Poisson Generalized Estimated Equation models, we compared characteristics of index clients who did and did not name additional partners and assessed HIV diagnoses and characteristics of partners named during initial versus follow-up visits. The 872 female index clients who accepted APS named 3461 male partners, of whom 2920 (84%) were successfully contacted and HIV tested. Of 1819 male partners named at the initial visit, 430 (23.6%) were previously diagnosed and 90 (4.9%) were newly diagnosed with HIV. Of 1101 male partners named at follow-up visits, 335 (30.4%) were previously diagnosed and 193 (17.5%) were newly diagnosed with HIV. Among partners tested, those named at follow-up visits were 3.9 times more likely to be newly diagnosed with HIV than those named at the initial visit (Relative Risk = 3.88, 95%CI = 3.00–4.98) and were more likely to report behaviors associated with HIV transmission, including having sex with >1 partner (p < 0.001) and with a partner at risk of HIV or with unknown HIV status (p = 0.01). Continuing partner elicitation for APS for 12 months after the initial visit was associated with a higher likelihood of identifying male partners at increased HIV risk compared to those initially named and increased the number of new HIV diagnoses.

  • Open Access

    A cross‐sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV‐1 in tenofovir disoproxil fumarate‐based pre‐exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa

    by Urvi M. Parikh, Lauren D. Kudrick, Lisa Levy, Everline Bosek, Bhavna H. Chohan, Irene Mukui, Sarah Masyuko, Nonhlanhla Ndlovu, Imelda Mahaka, Owen Mugurungi, et al.

    Introduction: The ongoing rollout of oral tenofovir‐based pre‐exposure prophylaxis (PrEP) has the potential to reduce HIV‐1 incidence, but HIV drug resistance (HIVDR) in individuals who acquire HIV‐1 on PrEP could threaten the treatment effectiveness of overlapping antiretrovirals (tenofovir/emtricitabine), contribute to development of resistance, and undermine HIV control efforts. Accordingly, the Global Evaluation of Microbicide Sensitivity (GEMS) project was established to monitor HIVDR in PrEP rollout programmes in Southern and Eastern Africa. Methods: GEMS monitored resistance in >100,000 estimated persons who accessed PrEP through national programmes or implementation projects in Southern/Eastern Africa. Participants self‐reported demographics and PrEP adherence. HIV‐1 RNA and tenofovir‐diphosphate levels were measured in blood samples collected at the time of study enrolment from consenting participants diagnosed with HIV who had received PrEP. HIVDR mutations were detected by population genotyping. Results: Of 283 reported seroconversions on PrEP from December 2017 through September 2023, 255 (90%) individuals enrolled in GEMS, of which 81 (32%) were from Kenya, 77 (30%) from South Africa, 69 (27%) from Zimbabwe and 28 (11%) from Eswatini. Half (130; 51%) were 15–24 years of age at seroconversion, and three‐quarters (193; 76%) were female. Thirty‐four seroconversions occurred within 30 days of PrEP initiation. Tenofovir‐diphosphate levels were consistent with moderate to high levels (≥350 femtomoles per punch) in 53% (120 of 226) individuals with drug‐level data. Of 154 samples successfully genotyped, 34 (22%; 95% CI [16%, 30%]) had PrEP‐associated mutations; these included 27 samples with M184I/V, one sample with K65KR, and six samples with both K65R and M184I/V. Conclusions: The frequency of HIVDR mutations associated with tenofovir or emtricitabine among individuals diagnosed with HIV who had received PrEP (22%) exceeded background levels of transmitted nucleoside reverse transcriptase inhibitor resistance in Southern and Eastern Africa (≤5%) but people with PrEP‐associated mutations are likely to achieve virologic suppression with current first‐line antiretroviral therapy (ART). Improved screening for acute infection before initiating PrEP, surveillance of HIVDR with the introduction of new PrEP programmes and the monitoring of longer‐term ART outcomes in individuals who acquire HIV‐1 on PrEP will be essential to preserve antiretroviral options for both treatment and prevention.


  • Open Access

    A phylogenetic assessment of HIV-1 transmission trends among people who inject drugs from Coastal and Nairobi, Kenya

    by Hanley Kingston, George Nduva, Bhavna H Chohan, Loice Mbogo, Aliza Monroe-Wise, Betsy Sambai, Brandon L Guthrie, Eduan Wilkinson, Jennifer Giandhari, Sarah Masyuko, et al.

    Although recent modeling suggests needle-syringe programs have reduced parenteral HIV transmission among people who inject drugs (PWID) in Kenya, the prevalence in this population remains high (~14-20%, compared to ~4% in the larger population). Reducing transmission or acquisition requires understanding historic and modern transmission trends, but the relationship between the PWID HIV-1 sub-epidemic and the general epidemic in Kenya is not well understood. We incorporated 303 new (2018-2021) HIV-1 pol sequences from PWID and their sexual and injecting partners with 2,666 previously published Kenyan HIV-1 sequences to quantify relative rates and direction of HIV-1 transmissions involving PWID from the coast and Nairobi regions of Kenya. We used genetic similarity cluster analysis (thresholds: patristic distance <0.045 & <0.015) and maximum likelihood and Bayesian ancestral state reconstruction to estimate transmission histories at the population group (female sex workers, men who have sex with men, PWID, or general population) and regional (coast or Nairobi) levels. Of 1,081 participants living with HIV-1, 274 (25%) were not virally suppressed and 303 (28%) had sequences available. Of new sequences from PWID, 58% were in phylogenetic clusters at distance threshold <0.045. Only 21% of clusters containing sequences from PWID included a second PWID sequence. Sequences from PWID were similarly likely to cluster with sequences from female sex workers, men who have sex with men, and the general population. Ancestral state reconstruction suggested transmission to PWID from other populations was more common than from PWID to other populations. This study expands our understanding of the HIV-1 sub-epidemic among PWID in Kenya by incorporating 4-times more HIV-1 sequences from this population than prior studies. Despite recruiting many PWID from local sexual and injecting networks, we found low levels of linked transmission in this population. This may suggest lower relative levels of parenteral transmission in recent years and supports maintaining needle-syringe programs among PWID while also strengthening interventions to reduce HIV-1 sexual acquisition and transmission for this population.

  • Open Access

    Cost and Cost-Effectiveness of Distributing HIV Self-Tests within Assisted Partner Services in Western Kenya

    by Victor Mudhune, Monisha Sharma, Sarah Masyuko, Kenneth Ngure, George Otieno, Unmesha Roy Paladhi, David A. Katz, Edward Kariithi, Carey Farquhar, Rose Bosire

    Background: Assisted partner services (APS) is a recommended public health approach to promote HIV testing for sexual partners of individuals diagnosed with HIV. We evaluated the cost and cost-effectiveness of integrating oral HIV self-testing (HIVST) into existing APS programs. Methods: Within the APS-HIVST study conducted in western Kenya (2021–2022), we conducted micro-costing, time-and-motion, and provider surveys to determine incremental HIVST distribution cost (2022 USD). Using a decision tree model, we estimated the incremental cost per new diagnosis (ICND) for HIVST incorporated into APS, compared to APS with provider-delivered testing only. Scenario, parameter and probabilistic sensitivity analyses were conducted to explore influential assumptions. Results: The cost per HIVST distributed within APS was USD 8.97, largest component costs were testing supplies (38%) and personnel (30%). Under conditions of a facility-based testing uptake of <91%, or HIVST utilization rates of <27%, HIVST integration into APS is potentially cost-effective. At a willing-to-pay threshold of USD 1000, the net monetary benefit was sensitive to the effectiveness of HIVST in increasing testing rates, phone call rates, HIVST sensitivity, HIV prevalence, cost of HIVST, space allocation at facilities, and personnel time during facility-based testing. In a best-case scenario, the HIVST option was cheaper by USD 3037 and diagnosed 11 more cases (ICND = 265.82). Conclusions: Implementers and policy makers should ensure that HIVST programs are implemented under conditions that guarantee efficiency by focusing on facilities with low uptake for provider-delivered facility-based testing, while deliberately targeting HIVST utilization among the few likely to benefit from remote testing. Additional measures should focus on minimizing costs relating to personnel and testing supplies.


  • Partner Characteristics and HIV Outcomes Among Partners Reached by Phone Versus In-Person for Assisted Partner Services in Western Kenya

    by Unmesha Roy Paladhi, Edward MBChB Kariithi, George Msc Otieno, James P. Hughes, Harison Lagat, Monisha ScM Sharma, Sarah MBChB Masyuko, Paul Msc Macharia, Rose MBChB Bosire, Mary Msc Mugambi, et al.

    Background: Assisted partner services (APS) is an effective strategy for testing people with undiagnosed HIV, but there is limited information on the relative reach and effectiveness of phone versus in-person contact. Methods: We analyzed data from 31 facilities in Western Kenya providing APS to female index clients newly HIV diagnosed, their male partners, and female partners of men newly HIV diagnosed. Assisted partner services providers attempted contacting partners using phone first and, if unsuccessful, in-person in the community. Using log-linear mixed models, we estimated relative risks (RRs) between phone being the final contact method and partner characteristics and HIV outcomes. Results: From May 2018 to March 2020, 2534 female index clients named 7614 male partners, of whom 772 (10.1%) tested positive and named an additional 4956 non-index female partners. Of 11,912 (94.7%) partners reached, 5179 (43.5%) were via phone and 6733 (56.5%) in-person. Of 8076 testing-eligible partners, 99.7% tested and 11.2% first-time tested. Of those tested, 13.1% were newly diagnosed, of whom 87.0% linked to care. Newly diagnosed partners were less likely to have been reached by phone versus in-person (9.8% vs. 15.9%; adjusted relative risk, 0.61; 95% confidence interval, 0.53–0.70). Being reached by phone was not significantly associated with testing, first-time testing, or linkage to care. Conclusions: In an APS program that reached 94% of elicited partners, fewer than half were successfully contacted by phone. A combined phone and in-person approach is likely essential for equitable, effective APS.

  • Open Access

    Effectiveness of HIV self‐testing when offered within assisted partner services in Western Kenya (APS‐HIVST Study): a cluster randomized controlled trial

    by Unmesha Roy Paladhi, David A. Katz, George Otieno, James P. Hughes, Harison Lagat, Sarah Masyuko, Monisha Sharma, Paul Macharia, Rose Bosire, Mary Mugambi, et al.

    Introduction: Assisted partner services (APS) is an effective strategy for increasing HIV testing, new diagnosis, and linkage to care among sexual partners of people living with HIV (PLWH). APS can be resource intensive as it requires community tracing to locate each partner named and offer them testing. There is limited evidence for the effectiveness of offering HIV self‐testing (HIVST) as an option for partner testing within APS.Methods: We conducted a cluster randomized controlled trial comparing provider‐delivered HIV testing (Standard APS) versus offering partners the option of provider‐delivered testing or HIVST (APS+HIVST) at 24 health facilities in Western Kenya. Facilities were randomized 1:1 and we conducted intent‐to‐treat analyses using Poisson generalized linear mixed models to estimate intervention impact on HIV testing, new HIV diagnoses, and linkage to care. All models accounted for clustering at the clinic level and new diagnoses and linkage models were adjusted for individual‐level age, sex, and income a priori.Results: From March to December 2021, 755 index clients received APS and named 5054 unique partners. Among these, 1408 partners reporting a prior HIV diagnosis were not eligible for HIV testing and were excluded from analyses. Of the remaining 3646 partners, 96.9% were successfully contacted for APS and tested for HIV: 2111 (97.9%) of 2157 in the APS+HIVST arm and 1422 (95.5%) of 1489 in the Standard APS arm. In the APS+HIVST arm, 84.6% (1785/2111) tested via HIVST and 15.4% (326/2111) received provider‐delivered testing. Overall, 16.7% of the 3533 who tested were newly diagnosed with HIV (APS+HIVST = 357/2111 [16.9%]; Standard APS = 232/1422 [16.3%]). Of the 589 partners who were newly diagnosed, 90.7% were linked to care (APS+HIVST = 309/357 [86.6%]; Standard APS = 225/232 [97.0%]). There were no significant differences between the two arms in HIV testing (relative risk [RR]: 1.02, 95% CI: 0.96–1.10), new HIV diagnoses (adjusted RR [aRR]: 1.03, 95% CI: 0.76–1.39) or linkage to care (aRR: 0.88, 95% CI: 0.74–1.06).Conclusions: There were no differences between APS+HIVST and Standard APS, demonstrating that integrating HIVST into APS continues to be an effective strategy for identifying PLWH by successfully reaching and HIV testing >95% of elicited partners, newly diagnosing with HIV one in six of those tested, >90% of whom were linked to care.Clinical Trial Number: NCT04774835


  • Open Access

    Providing HIV‐assisted partner services to partners of partners in western Kenya: an implementation science study

    by Monisha Sharma, Barbara Wanjiku Mambo, Hanley Kingston, George Otieno, Sarah Masyuko, Harison Lagat, David A. Katz, Beatrice Wamuti, Paul Macharia, Rose Bosire, et al.

    Introduction: Assisted partner services (APS), or exposure notification and HIV testing for sexual partners of persons diagnosed HIV positive (index clients), is recommended by the World Health Organization. Most APS literature focuses on outcomes among index clients and their partners. There is little data on the benefits of providing APS to partners of partners diagnosed with HIV.Methods: We utilized data from a large‐scale APS implementation project across 31 facilities in western Kenya from 2018 to 2022. Females testing HIV positive at facilities were offered APS; those who consented provided contact information for all male sexual partners in the last 3 years. Male partners were notified of their potential HIV exposure and offered HIV testing services (HTS). Males newly testing positive were also offered APS and asked to provide contact information for their female partners in the last 3 years. Female partners of male partners (FPPs) were provided exposure notification and HTS. All participants with HIV were followed up at 12 months post‐enrolment to assess linkage‐to antiretroviral treatment (ART) and viral suppression. We compared HIV positivity, demographics and linkage outcomes among female index clients and FPPs.Results: Overall, 5708 FPPs were elicited from male partners, of whom 4951 received HTS through APS (87% coverage); 291 FPPs newly tested HIV positive (6% yield), an additional 1743 (35.2%) reported a prior HIV diagnosis, of whom 99% were on ART at baseline. At 12 months follow‐up, most FPPs were taking ART (92%) with very few adverse events: <1% reported intimate partner violence or reported relationship dissolution. FPPs were more likely than female index clients to report HIV risk behaviours including no condom use at last sex (45% vs. 30%) and multiple partners (38% vs. 19%).Conclusions: Providing HIV testing via APS to FPP is a safe and effective strategy to identify newly diagnosed females and achieve high linkage and retention to ART and can be an efficient means of identifying HIV cases in the era of declining HIV incidence. The high proportion of FPPs reporting HIV risk behaviours suggests APS may help interrupt community HIV transmission via increased knowledge of HIV status and linkage to treatment.


  • Open Access

    “We only trust each other”: A qualitative study exploring the overdose risk environment among persons who inject drugs living with HIV in Nairobi, Kenya

    by Megan Maurano, David Bukusi, Sarah Masyuko, Rose Bosire, Esther Gitau, Brandon L. Guthrie, Aliza Monroe-Wise, Helgar Musyoki, Mercy Apiyo Owuor, Betsy Sambai, et al.

    In Kenya, overdose remains a major public health concern with approximately 40% of persons who inject drugs (PWID) reporting personal overdoses. PWID living with HIV (PWID-LH) are particularly vulnerable to experiencing fatal and non-fatal overdoses because of the surrounding physical, social, economic, and political environments, which are not fully understood in Kenya. Through qualitative inquiry, this study characterizes Kenya’s overdose risk environment. Participants were purposively recruited from a larger cohort study from September to December 2018 using the following inclusion criteria: HIV-positive, age ≥18 years, injected drugs in the last year, and completed cohort study visits. Semi-structured interviews explored experiences of personal and observed overdoses, including injection settings, sequence of events (e.g., pre-, during, and post-overdose), safety strategies, and treatment. Interviews were transcribed, translated (Swahili to English), reviewed, and analyzed thematically, applying a risk environment framework. Nearly all participants described personal and/or observed overdose experiences (96%) and heroin was the most frequently reported substance (79%). Overdose precursors included increased consumption, polysubstance use, recent incarceration, and rushed injections. There were also indications of female-specific precursors, including violence and accessing prefilled syringes within occupational settings. Overdose safety strategies included avoiding injecting alone, injecting drugs incrementally, assessing drug quality, and avoiding polysubstance use. Basic first-aid techniques and naloxone use were common treatment strategies; however, naloxone awareness was low (25%). Barriers to treatment included social network abandonment, police discrimination, medical stigma, fatalism/religiosity, medical and transportation costs, and limited access to treatment services. In Kenya, the overdose risk environment highlights the need for comprehensive overdose strategies that address the physical, social, economic, and political environments. Morbidity and mortality from overdose among PWID-LH could be reduced through overdose prevention initiatives that support harm reduction education, naloxone awareness, and access, destigmatization of PWID, and reforming punitive policies that criminalize PWID-LH.


  • Virologic Nonsuppression and HIV Drug Resistance Among People Who Inject Drugs and Their Sexual and Injecting Partners in Kenya

    by Bhavna H. Chohan, Hanley Kingston, Ashley S. Tseng, Betsy Sambai, Brandon L. Guthrie, Eduan Wilkinson, Jennifer Giandhari, Loice W. Mbogo, Aliza Monroe-Wise, Sarah Masyuko, et al.

    We evaluated the prevalence and correlates of HIV viral nonsuppression and HIV drug resistance (HIV-DR) in a cohort of people who inject drugs living with HIV (PWID-LH) and their sexual and injecting partners living with HIV in Kenya. HIV-DR testing was performed on participants with viral nonsuppression. Of 859 PWID-LH and their partners, 623 (72.5%) were on antiretroviral therapy (ART) ≥4 months and 148/623 (23.8%) were not virally suppressed. Viral nonsuppression was more common among younger participants and those on ART for a shorter duration. Among 122/148 (82.4%) successfully sequenced samples, 55 (45.1%) had detectable major HIV-DR mutations, mainly to non-nucleoside and nucleotide reverse transcriptase inhibitors (NNRTI and NRTI). High levels of HIV-DR among those with viral nonsuppression suggests need for viral load monitoring, adherence counseling, and timely switching to alternate ART regimens in this key population.